{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:04:33Z","timestamp":1761897873031,"version":"3.37.3"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000218","U22A20290"],"award-info":[{"award-number":["82000218","U22A20290"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2020J01222713","2020GGB054","2020J011246"],"award-info":[{"award-number":["2020J01222713","2020GGB054","2020J011246"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010166","name":"Xiamen Municipal Bureau of Science and Technology","doi-asserted-by":"publisher","award":["3502Z20209008","3502Z20209003"],"award-info":[{"award-number":["3502Z20209008","3502Z20209003"]}],"id":[{"id":"10.13039\/100010166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recent evidence suggests that bispecific antibodies (BsAbs) exhibit promising efficacy and low toxicity even in heavily treated non-Hodgkin B-cell lymphoma (B-NHL). However, the role of BsAbs in previously untreated NHL and the efficacy and safety of BsAbs used in combination remain uncertain. We summarized data published at the 64th American Society of Hematology (ASH) Annual Meeting on BsAb monotherapy or combination therapy for first-line or relapsed\/refractory B-NHL. BsAb monotherapy in elderly\/unfit newly diagnosed (ND) DLBCL patients achieved ORR and CR rates of 56% and 43%, respectively. In addition, BsAbs combined with chemotherapy or other novel agents raised the ORR higher than 50% without increasing the incidence of grade\u2009\u2265\u20093 CRS. We conclude that BsAb monotherapy or combination therapy for first-line or relapsed\/refractory B-NHL has high efficacy and satisfactory safety.<\/jats:p>","DOI":"10.1186\/s40164-023-00404-3","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T15:11:34Z","timestamp":1682089894000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the American society of hematology 2022 annual meeting"],"prefix":"10.1186","volume":"12","author":[{"given":"Zhijuan","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhifeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"issue":"Supplement 1","key":"404_CR1","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1182\/blood-2022-157691","volume":"140","author":"NL Bartlett","year":"2022","unstructured":"Bartlett NL, Sehn LH, Matasar MJ, Schuster SJ, Assouline S, Giri P, Kuruvilla J, Canales M, Dietrich S, Fay K, Ku M, Nastoupil LJ, Wei MC, Yin S, To I, Huang H, Min J, Penuel E, Budde LE. Mosunetuzumab Monotherapy demonstrates durable efficacy with a Manageable Safety Profile in patients with Relapsed\/Refractory follicular lymphoma who received \u2265 2 prior therapies: updated results from a pivotal phase II study. Blood. 2022;140(Supplement 1):1467\u201370.","journal-title":"Blood"},{"issue":"Supplement 1","key":"404_CR2","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1182\/blood-2022-158404","volume":"140","author":"TM Kim","year":"2022","unstructured":"Kim TM, Taszner M, Cho S-G, Novelli S, Le Gouill S, Poon ML, Villasboas JC, Champion R, Bachy E, Guidez S, Alonso Alonso A, Jagadeesh D, Merli M, Tucker D, Cai J, De Leite C, Zhu M, Chaudhry A, Mohamed H, Ambati SR, Luminari S. Odronextamab in patients with Relapsed\/Refractory (R\/R) follicular lymphoma (FL) Grade 1-3a: results from a prespecified analysis of the pivotal phase II study ELM-2. Blood. 2022;140(Supplement 1):2280\u20132.","journal-title":"Blood"},{"issue":"Supplement 1","key":"404_CR3","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1182\/blood-2022-158406","volume":"140","author":"W-S Kim","year":"2022","unstructured":"Kim W-S, Kim TM, Cho S-G, Jarque I, Iskierka-Ja\u017cd\u017cewska E, Poon ML, Prince HM, Oh SY, Lim F, Carpio C, Tan T-D, Ayyappan S, Gutierrez A, Li J, Ufkin M, Zhu M, Chaudhry A, Mohamed H, Ambati SR, Walewski J. Odronextamab in patients with Relapsed\/Refractory (R\/R) diffuse large B-Cell lymphoma (DLBCL): results from a prespecified analysis of the pivotal phase II study ELM-2. Blood. 2022;140(Supplement 1):1070\u20131.","journal-title":"Blood"},{"issue":"Supplement 1","key":"404_CR4","doi-asserted-by":"publisher","first-page":"9443","DOI":"10.1182\/blood-2022-158245","volume":"140","author":"T Phillips","year":"2022","unstructured":"Phillips T, Thieblemont C, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Do YR, Feldman TA, Gasiorowski R, Jurczak W, Kim TM, Lewis DJ, van der Poel M, Poon ML, Kilavuz N, Cota Stirner M, Soong D, Chiu C, Chen M, Sacchi M, Elliot B, Hutchings M, Lugtenburg P. Epcoritamab Monotherapy provides deep and durable responses including minimal residual disease (MRD) negativity: novel subgroup analyses in patients with Relapsed\/Refractory (R\/R) large B-Cell lymphoma (LBCL). Blood. 2022;140(Supplement 1):9443\u20135.","journal-title":"Blood"},{"issue":"Supplement 1","key":"404_CR5","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1182\/blood-2022-157768","volume":"140","author":"AJ Olszewski","year":"2022","unstructured":"Olszewski AJ, Avigdor A, Babu S, Levi I, Eradat H, Abadi U, Holmes H, McKinney M, Woszczyk D, Giannopoulos K, Jurczak W, Dunshee D, Yang A, Zhou M, Qayum N, Sellam G, Horowitz NA. Mosunetuzumab Monotherapy continues to demonstrate promising efficacy and durable complete responses in Elderly\/Unfit patients with previously untreated diffuse large B-Cell lymphoma. Blood. 2022;140(Supplement 1):1778\u201380.","journal-title":"Blood"},{"issue":"Supplement 1","key":"404_CR6","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1182\/blood-2021-146629","volume":"138","author":"KM Linton","year":"2021","unstructured":"Linton KM, Wahlin B, Leep\u00e4 S, Morschhauser F, Elliot B, Liu T, Cota Stirner M, Abbas A, Falchi L. Subcutaneous epcoritamab in combination with R 2 (Rituximab and Lenalidomide) in patients with relapsed or refractory follicular lymphoma: preliminary results from a phase 1\/2 trial. Blood. 2021;138(Supplement 1):3535\u20135.","journal-title":"Blood"},{"issue":"Supplement 1","key":"404_CR7","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1182\/blood-2022-158232","volume":"140","author":"L Falchi","year":"2022","unstructured":"Falchi L, Leslie LA, Belada D, Kopeckova K, Offner F, Brody J, Canales M, Mart\u00edn Garc\u00eda-Sancho A, Nijland M, Andersson P-O, Awan FT, Christensen JH, Drott K, Hellstr\u00f6m M, Lewerin C, Narkhede M, Snauwaert S, Wahlin BE, Rana A, Abbas A, Wang L, Dinh M, Vermaat JSP, Abrisqueta P. Subcutaneous epcoritamab in combination with rituximab + lenalidomide (R2) for first-line treatment of follicular lymphoma: initial results from Phase 1\/2 Trial. Blood. 2022;140(Supplement 1):1471\u20133.","journal-title":"Blood"},{"issue":"Supplement 1","key":"404_CR8","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1182\/blood-2022-158278","volume":"140","author":"P Abrisqueta","year":"2022","unstructured":"Abrisqueta P, Cordoba R, Falchi L, de Vos S, Nijland M, Offner F, Wu J, Bykhovski I, Wang L, Rana A, Phillips T. Subcutaneous epcoritamab + R-Dhax\/C in patients with relapsed or refractory diffuse large B-Cell lymphoma eligible for autologous stem cell transplant: updated phase 1\/2 results. Blood. 2022;140(Supplement 1):1068\u20139.","journal-title":"Blood"},{"key":"404_CR9","doi-asserted-by":"crossref","unstructured":"Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and \u2265 65 Years with Relapsed\/Refractory Diffuse Large B-Cell Lymphoma (R\/R DLBCL) and \u2265 1 Prior Therapy: Subgroup Analysis of a Phase Ib\/II Study. Blood. 2022;140(Supplement 1):3757\u20133759.","DOI":"10.1182\/blood-2022-159594"},{"issue":"Supplement 1","key":"404_CR10","doi-asserted-by":"publisher","first-page":"9461","DOI":"10.1182\/blood-2022-157011","volume":"140","author":"M Hutchings","year":"2022","unstructured":"Hutchings M, Carlo-Stella C, Gritti G, Bosch F, Morschhauser F, Townsend W, Offner F, Walter HS, Ghesquieres H, Houot R, Cartron G, Dimier N, Fowler S, Harrop E, Herter S, Keelara A, Korfi K, Luong J, Mueller C, Nutbrown R, Palldino G, Whayman M, Prieto I, Mycroft SL, Rukina D, Lechner KE, Dickinson M. CD19 4-1BBL (RO7227166) a Novel Costimulatory bispecific antibody can be safely combined with the T-Cell-engaging bispecific antibody glofitamab in relapsed or refractory B-Cell Non-Hodgkin Lymphoma. Blood. 2022;140(Supplement 1):9461\u20133.","journal-title":"Blood"},{"issue":"Supplement 1","key":"404_CR11","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1182\/blood-2022-157732","volume":"140","author":"MS Topp","year":"2022","unstructured":"Topp MS, Tani M, Dickinson M, Ghosh N, Santoro A, Pinto A, Bosch F, Fox CP, L\u00f3pez-Guillermo A, Carlucci C, Wu C, Humphrey K, Baumlin P, Barrett M, Qayum N, Morschhauser F. Glofitamab Plus R-CHOP induces high response rates and a Favorable Safety Profile in patients with previously untreated diffuse large B-Cell lymphoma (DLBCL): results from a phase ib study. Blood. 2022;140(Supplement 1):1775\u20137.","journal-title":"Blood"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-023-00404-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-023-00404-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-023-00404-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T15:17:14Z","timestamp":1682090234000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-023-00404-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["404"],"URL":"https:\/\/doi.org\/10.1186\/s40164-023-00404-3","relation":{},"ISSN":["2162-3619"],"issn-type":[{"type":"electronic","value":"2162-3619"}],"subject":[],"published":{"date-parts":[[2023,4,21]]},"assertion":[{"value":"10 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant conflicts.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is not applicable for this summary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This is not applicable for this summary.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"41"}}